Ambaw Bellete compensation by year
CG Oncology Summary Compensation Table · all 3 fiscal years held| Component | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Salary | $322,000 | $511,935 | $537,941 |
| Bonus | $189,500 | $0 | $0 |
| Stock awards | $0 | $0 | $0 |
| Option awards | $1,967,465 | $4,471,424 | $3,967,601 |
| Non-equity incentive | $179,740 | $242,996 | $268,971 |
| Pension and deferred compensation | $0 | $0 | $0 |
| All other | $369,970 | $15,036 | $40,879 |
| Total | $3,028,675 | $5,241,391 | $4,815,391 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: CG Oncology, Inc. DEF 14A filed April 24, 2026, accession 0001193125-26-177395, and prior-year filings. Open the filing on EDGAR.
How this page was built: the CG Oncology, Inc. filed document, accession 0001193125-26-177395. Every figure is read from that document and cited to the page and table it appears in. Filed April 24, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| Option | 171,114 | — | $3.72 |
| Option | 6,552 | — | $1.82 |
| Option | 124,313 | — | $36.63 |
| Option | 26,208 | — | $12.59 |
| Option | 237,347 | — | $20.11 |
Per the Outstanding Equity Awards at Fiscal Year-End table in CG Oncology, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Change-in-control & termination
estimated payments CG Oncology discloses, by trigger · FY2025| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Change in control and involuntary termination | $1,344,828 | $13,175,911 | $109,620 | $14,630,359 |
| Resignation for good reason, no change in control | $1,075,862 | $13,175,911 | $82,215 | $14,333,988 |
| Involuntary termination without cause | $1,075,862 | $13,175,911 | $82,215 | $14,333,988 |
| Change in control and resignation for good reason | $1,344,828 | $13,175,911 | $109,620 | $14,630,359 |
Per the Potential Payments Upon Termination or Change in Control table in CG Oncology, Inc.'s FY2025 proxy. Estimates as the company printed them; a dash means it printed no figure.
CG Oncology’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Arthur Kuan | Chairman and Chief Executive Officer | $11,928,401 |
| Ambaw Bellete · this page | President and Chief Operating Officer | $4,815,391 |
| Vijay Kasturi | Chief Medical Officer | $3,599,947 |
| Joshua Patterson | General Counsel, Chief Compliance Officer, and Secretary | $2,364,380 |
| Corleen Roche | Prior Chief Financial Officer | $2,322,299 |
| Robert Lapetina | Prior Interim Principal Financial and Accounting Officer | $645,297 |
| Jim DeTore | Chief Financial Officer | $96,000 |
The full CG Oncology compensation record
free company briefThis page is one person within CG Oncology's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the CG Oncology proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order CG Oncology's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are CG Oncology's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order CGON
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.